Pfizer Ltd logo

Pfizer Ltd

PFIZER NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹22,874 Cr
Volatility
High Risk
P/E Ratio
31.05
EBITDA
₹1,092 Cr
Return on Equity
17.19%
Debt to Equity
0.02
Book Value
₹918.71
EPS
₹131.73
52W High
₹5,873.5
52W Low
₹4,360.1

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Pfizer Ltd insights

39 extracted metrics + investor summaries across FY14–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

3
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 58.3%

Weaknesses

1
  • The company has delivered a poor sales growth of 2.39% over past five years.

Growth Rate

Revenue Growth
10.35% ↗
Net Income Growth
-5.89% ↘
Cash Flow Change
46.66% ↗
ROE
-5.55% ↘
ROCE
-2.80% ↘
EBITDA Margin (Avg.)
8.44% ↗

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 9h ago
AI opinion · based on fundamentals
Risk medium

Pfizer Ltd is an almost debt-free MNC pharma company with a market cap of ~₹22,874 Cr trading at a PE of ~31x. After two years of revenue decline (FY23: -7%, FY24: -10%), the company returned to growth with FY25 revenue of ₹2,281 Cr (+4%) and FY26 revenue of ₹2,520 Cr (+10.5%). Profit compounding at 10% over 10 years and a consistent 58% dividend payout provide stability, but sluggish 5-year sales CAGR of just 2% and stock returns of -3% over 5 years highlight limited growth momentum.

Bull Case 8
  • Virtually debt-free balance sheet provides financial resilience and flexibility for future investments
  • FY26 revenue grew 10.5% YoY to ₹2,520 Cr, marking a clear recovery after two consecutive years of decline
  • Consistent dividend payout ratio of 58.3% with FY26 final dividend of ₹75/share, translating to a yield of ~1.5%
  • 10-year compounded profit growth of 10% demonstrates long-term earnings consistency
  • EBITDA margin improved to 32.4% in FY25 from 29% in FY24, indicating operating leverage and cost discipline
  • ROE sustained at 16-18% over 3, 5, and 10-year periods reflects efficient capital allocation for a debt-free company
  • Backed by global parent Pfizer Inc., providing access to a pipeline of patented molecules and R&D without significant local spending
  • TTM sales growth of 11% and TTM profit growth of 14% indicate the recent growth trajectory is accelerating
Bear Case 8
  • 5-year compounded sales CAGR of only 2% signals structurally low top-line growth versus domestic pharma peers
  • PE of ~31x is expensive for a company growing revenue at low single digits over extended periods; 10-year mean PE is 31.6x offering no valuation cushion
  • 5-year stock CAGR of -3% shows the stock has destroyed value for medium-term investors despite underlying profit growth
  • Q4 FY26 net profit fell 39.6% YoY to ₹200 Cr, indicating earnings volatility and quarter-to-quarter lumpiness
  • FY25 full-year net profit of ₹722 Cr declined ~5.9% YoY in FY26 on an annual basis, showing profit growth is inconsistent
  • Revenue declined in both FY23 (-7.1%) and FY24 (-9.6%) largely due to tapering of COVID-related products, exposing base-business growth weakness
  • Limited product launches and dependence on parent company's pipeline decisions constrains independent growth levers in India
  • Market cap of ₹22,874 Cr with a PB of 5.46x leaves limited margin of safety if earnings disappoint

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 3h ago
Headwinds 2
  • CFO resignation in October Jul 27

    CFO Amit Agarwal will resign as Executive Director and Board member on October 8, 2026, to pursue an external opportunity, creating a leadership gap in finance.

  • Premarin Cream supply halted Jul 16

    Pfizer temporarily discontinued Premarin Vaginal Cream in India due to supply challenges, with no confirmed timeline to resume.

Positives 4
  • Q2 EPS beats estimates by 12% Aug 4

    Pfizer reported Q2 adjusted EPS of $0.77, beating the $0.69 consensus by 11.59%. Sales rose 2.3% YoY to $15.034 billion.

  • ₹75 dividend declared at AGM Jul 28

    Pfizer approved a ₹75 per share dividend for FY26 at its 75th AGM on July 28, 2026.

  • Q1 revenue and margins expand Jul 28

    Q1 revenue grew to ₹6.5B from ₹6B YoY, EBITDA margin expanded to 37.9% from 34.83%, and net profit rose to ₹2.04B from ₹1.9B.

  • RFID meds partnership with Bluesight Jul 22

    Pfizer partnered with Bluesight to provide source-tagged RFID medications under SmartDose, with availability planned for H2 2026.

Neutral 1
  • Premarin supply under review Jul 16

    Pfizer is exploring options to resume Premarin Vaginal Cream supply in India but has not provided a specific restart date.

TL;DR: Pfizer is delivering solid financial performance with Q2 EPS beating estimates by 12% and Q1 showing broad-based margin expansion to 37.9% EBITDA. The ₹75 dividend signals confidence in cash generation. Key risks include the CFO's upcoming departure in October and a temporary product supply disruption. The trend is improving on financials, but leadership continuity and supply chain execution bear watching in the near term.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
531
575
540
547
563
589
538
592
603
642
645
629
653
Expenses
421
393
387
357
385
399
392
364
393
412
417
393
406
Operating Profit
111
183
153
189
177
189
146
228
210
230
228
236
248
OPM %
21%
32%
28%
35%
32%
32%
27%
38%
35%
36%
35%
38%
38%
Other Income
33
36
44
75
42
43
43
217
67
42
-20
50
45
Interest
3
3
3
7
2
2
2
3
3
2
2
2
1
Depreciation
16
15
18
14
15
15
15
16
14
14
14
15
14
PBT
126
201
176
244
203
215
172
426
260
255
192
269
277
Tax %
26%
26%
26%
27%
26%
26%
26%
22%
26%
26%
26%
26%
26%
Net Profit
94
149
130
179
151
158
128
331
192
189
142
200
204
EPS in Rs
20.44
32.56
28.41
39.1
32.94
34.61
27.89
72.34
41.91
41.32
31
43.68
44.7
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,853
2,012
1,966
1,969
2,082
2,152
2,239
2,611
2,425
2,193
2,281
2,520
2,570
Expenses
1,438
1,579
1,616
1,468
1,516
1,578
1,526
1,775
1,616
1,555
1,540
1,615
1,628
Operating Profit
414
433
350
501
566
574
712
836
809
638
742
904
942
OPM %
22%
22%
18%
25%
27%
27%
32%
32%
33%
29%
33%
36%
37%
Other Income
44
97
232
114
167
183
81
63
134
185
344
139
116
Interest
2
1
2
1
2
11
15
11
13
15
8
10
8
Depreciation
250
58
63
66
71
103
109
115
106
62
61
58
58
PBT
207
470
517
548
660
642
669
773
824
746
1,016
976
993
Tax %
66%
35%
35%
34%
35%
21%
26%
21%
24%
26%
24%
26%
—
Net Profit
70
305
337
360
429
509
498
613
624
551
768
722
735
EPS in Rs
15.26
66.67
73.62
78.71
93.79
111
109
134
136
121
168
158
161
Div. Payout %
82%
22%
27%
25%
24%
297%
32%
26%
29%
29%
98%
48%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
46
46
46
46
46
46
46
46
46
46
46
46
Reserves
1,927
2,118
2,373
2,637
2,966
3,350
2,347
2,819
3,162
3,550
4,172
4,157
Borrowings
2
2
2
2
2
2
63
39
41
40
108
70
Other Liabilities
638
722
840
1,004
926
1,007
810
997
752
593
585
649
Total Liabilities
2,614
2,888
3,261
3,690
3,940
4,405
3,266
3,901
4,001
4,229
4,911
4,922
Fixed Assets
944
925
902
950
886
973
894
869
749
713
724
678
CWIP
13
3
15
1
0
1
3
1
8
0
8
20
Investments
43
37
0
0
0
0
0
0
0
0
0
0
Other Assets
1,614
1,923
2,343
2,739
3,054
3,432
2,369
3,030
3,244
3,516
4,180
4,224
Total Assets
2,614
2,888
3,261
3,690
3,940
4,405
3,266
3,901
4,001
4,229
4,911
4,922
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
113
345
329
332
98
323
427
667
356
257
660
968
Investing
68
-701
-250
-238
35
1,530
-469
-575
-36
54
-71
-562
Financing
-1
-62
-83
-110
-110
-164
-1,571
-181
-346
-235
-205
-798
Net Cash Flow
181
-417
-3
-17
23
1,690
-1,613
-88
-26
75
383
-392
Free Cash Flow
93
398
394
262
125
343
410
654
292
291
783
944
CFO/OP
62
120
146
105
59
93
89
107
81
64
110
105
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
32
26
20
29
30
29
18
20
23
31
31
26
Inventory Days
191
167
148
147
189
198
199
173
175
200
214
195
Days Payable
165
157
178
245
213
197
130
102
91
77
68
89
Cash Conversion Cycle
58
36
-10
-69
6
31
87
91
107
154
177
132
Working Capital Days
7
-9
-47
-57
-16
-8
3
-14
1
24
23
9
ROCE %
24%
22%
17%
21%
23%
20%
23%
29%
26%
22%
21%
24%

Shareholding Pattern

As of Jun 2026
Promoters 63.92%
DIIs 17.80%
Public 12.04%
Others 4.59%
FIIs 1.65%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
63.92%
63.92%
63.92%
63.92%
63.92%
63.92%
63.92%
63.92%
63.92%
63.92%
63.92%
63.92%
63.92%
63.92%
63.92%
63.92%
63.92%
63.92%
63.92%
63.92%
63.92%
63.92%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
2.82%
0.00%
3.33%
3.22%
3.54%
2.75%
2.18%
2.39%
2.60%
2.71%
2.81%
1.65%
DIIs
13.08%
8.98%
8.98%
8.84%
8.57%
7.91%
14.85%
14.93%
14.89%
14.89%
15.01%
15.15%
15.33%
15.84%
16.03%
16.79%
17.10%
17.23%
17.10%
17.05%
16.89%
17.80%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
15.03%
14.11%
14.11%
14.25%
14.19%
14.08%
13.94%
13.71%
13.70%
13.69%
13.61%
13.21%
12.90%
12.55%
12.15%
12.12%
12.34%
12.02%
12.08%
11.93%
11.87%
12.04%
Others
7.97%
12.98%
12.98%
12.99%
13.32%
14.08%
7.29%
7.43%
7.49%
7.50%
4.64%
7.72%
4.52%
4.46%
4.35%
4.41%
4.45%
4.43%
4.29%
4.39%
4.51%
4.59%
No. of Shareholders
1,45,980
1,21,153
1,21,153
1,26,808
1,25,287
1,23,449
1,22,028
1,17,950
1,17,194
1,15,988
1,16,948
1,12,456
1,09,214
1,06,098
98,824
1,05,015
1,08,261
1,03,222
1,03,480
1,00,933
99,545
1,02,478

Documents

Frequently Asked Questions about Pfizer Ltd

What does Pfizer Ltd do?
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors...
Where is Pfizer Ltd (PFIZER) listed?
Pfizer Ltd is listed on the Indian stock exchanges. It is listed on NSE: PFIZER and BSE: 500680. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Pfizer Ltd belong to?
Pfizer Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Pfizer Ltd?
Pfizer Ltd has a market capitalisation of approximately ₹22873.87 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Pfizer Ltd?
The Price-to-Earnings (PE) ratio of Pfizer Ltd is 31.05. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Pfizer Ltd?
Over the past 52 weeks, Pfizer Ltd has traded between a low of ₹4,360.1 and a high of ₹5,873.5. This range helps investors understand the stock's price volatility and recent trading levels.
Does Pfizer Ltd pay dividends?
Yes, Pfizer Ltd has a dividend yield of 1.49%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Pfizer Ltd?
Pfizer Ltd has a Return on Equity (ROE) of 17.19%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Pfizer Ltd on Tapetide?
On Tapetide, you can view Pfizer Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors primarily in India.[1] It is the 3rd largest multinational pharmaceutical company in India.[2]

Website pfizerindia.com
CEO Ms. Meenakshi Nevatia
Employees 1,598
Listed 1999-04-28
Face Value ₹ 10
Issued Size 4,57,47,732

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List